170 as multiplicity adjusted p values. Statistical significance was designated when p < 0.05 and all p-171 values were subsequently reported. 175 To determine the appropriate concentration of R-roscovitine for comparing different 176 hERG constructs, we wanted to establish the effectiveness of R-roscovitine inhibition on wild-177 type (WT) hERG channels in Xenopus oocytes. The half-maximal inhibitory concentration (IC 50 ) 178 of tail currents for R-roscovitine with WT hERG was determined previously in HEK-293 cells 179 (27 µM), but Xenopus oocytes are known to require higher drug doses [25] . Therefore, we 180 injected cRNA for WT hERG into Xenopus oocytes and recorded potassium currents 2-7 days 181 later (see methods). The currents were elicited using a 2-second pulse protocol consisting of a 1-182 second depolarization to +40 mV followed by a 1-second repolarization to -50 mV, during which 183 tail currents were measured (Fig 1B) . This pulse protocol was repeated either every 5 seconds for 184 R-roscovitine concentrations applied in a randomized order (100, 300, 30, and 10 µM) or every 185 12 seconds for ascending R-roscovitine concentrations (10, 30, 100, 300, and 1000 µM), with the 186 various drug concentrations being repeatedly applied and washed off (Fig 1C) . Fitting the 187 fractional block of hERG tail currents with a Hill equation resulted in an IC 50 for WT of 196 ± 12 188 µM (Fig 1D) . Thus, we used 200 µM R-roscovitine for studying inhibition levels of WT and 189 mutant hERG channels. 250 mV, n = 14, one-way ANOVA). Error bars represent standard errors; some error bars are smaller 251 than the symbols. * = P < 0.05, ** = P < 0.01, and *** = P < 0.001.
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R-roscovitine-mediated inhibition of WT hERG in Xenopus oocytes
252
253 Comparison of WT and mutant hERG channels in the absence of R-254 roscovitine 255 Next, we examined currents from hERG mutants to establish their baseline properties 256 before applying R-roscovitine. hERG block is commonly associated with residues located near 257 the selectivity filter (e.g. S624) and on the S6 helices (e.g. Y652) [32, 33] . Therefore, single-258 mutant channels S624A and Y652A were expressed in Xenopus oocytes and subjected to a step 259 depolarization protocol (Fig 3A, top) .
Step I-V curves for WT, S624A, and Y652A showed 260 maximum step currents at 0 mV, -10 mV, and +10 mV, respectively (Fig 3A, bottom) . At +60 284 weaken or abolish drug inhibition [35] . Applying the step depolarization protocol to S624A 285 hERG channels resulted in currents with typical n-shaped step I-V curves and inhibition occurred 286 at intermediate voltages (i.e. between -30 mV and +30 mV; Fig 4B) . Surprisingly, mutating the 287 S624 residue did not attenuate 200 µM R-roscovitine current inhibition: S624A and WT step 288 current inhibition were almost identical over a range of step voltages (p > 0.05 for WT vs.
289 S624A between +10 mV and +60 mV, n ≥ 9, one-way ANOVA; Fig 4C) . In fact, at a few 290 intermediate voltages, the inhibition of S624A was almost 25% larger than WT inhibition (p < 291 0.05 for WT vs. S624A between -20 mV and 0 mV, n ≥ 9, one-way ANOVA).
292
S624A tail I-V curves had typical sigmoidal curves and a V 0.5 of activation of -17.7 ± 3.2 293 mV before R-roscovitine application (Fig 4D) . Although there seemed to be a shift during R-294 roscovitine block (S624A V 0.5,Rosc = -3.3 ± 6.1 mV), this shift was not statistically significant (p = 295 0.09, n = 9, paired t-test). Similar to the enhanced step inhibition at intermediate step voltages, 296 S624A tail current inhibition was significantly stronger than WT channel inhibition over a range 297 of depolarized voltages (p < 0.05 for WT vs. S624A between -20 mV and +50 mV, n ≥ 9, one-298 way ANOVA; Fig 4E) . At +50 mV, S624A tail inhibition by 200 µM R-roscovitine reached 66.8 299 ± 3.6%, which was larger than WT inhibition (49.9 ± 2.8%) at the same step voltage (p = 0.0012, 300 n ≥ 9 , one-way ANOVA). When we measured dose-response curves, S624A IC 50 (152 ± 22 µM) 301 was smaller than WT IC 50 (196 ± 12 µM), but this difference did not reach statistical signifiance 302 (p > 0.05 for WT vs. S624A, n ≥ 9, one-way ANOVA; Fig 4F) . The persistence of inhibition 303 suggested that S624 may not be required for R-roscovitine inhibition. It remained unclear, 304 however, as to why inhibition levels increased at some voltages in S624A hERG. The Y652A mutation weakens R-roscovitine inhibition of hERG 325 channels 326 We next tested the importance of the Y652 residue, which is a key binding target for 327 several hERG inhibitors [36] . Using the same step depolarization as before (Figs. 2, 3, 4) , step 328 and tail currents were elicited in the presence or absence of 200 µM R-roscovitine (Fig 5A) .
329 Unlike S624A, Y652A hERG exhibited a reduced inhibition of step current compared to WT 330 hERG (Fig 5B, C ; p < 0.05 for WT vs. Y652A between -20 mV and +10 mV, n ≥ 9, one-way 331 ANOVA).
332
Analogous to WT tail I-V curves, Y652A tail I-V curves were shifted to more 333 hyperpolarized voltages by R-roscovitine (V 0.5 = -16.5 ± 1.0 mV vs. V 0.5,Rosc = -19.6 ± 0.5, p = 334 0.0094, n = 11, paired t-test; Fig 5D) . Percent tail inhibition in Y652A was moderately reduced 335 compared to WT between -20 mV and +60 mV, and showed the highest levels of inhibition at 336 large depolarized potentials (p < 0.05 for WT vs. Y652A, n ≥ 9, one-way ANOVA; Fig 5E) .
337 Furthermore, the Y652A IC 50 (567 ± 122 µM) was ~ 2.75-fold larger than WT (196 ± 12 µM; p 338 = 0.0005 for WT vs. Y652A, n ≥ 8, one-way ANOVA; Fig 5F) . The attenuated step and tail 339 current inhibition of Y652A with 200 µM R-roscovitine, as well as the difference in IC 50 values 340 between Y652A and WT hERG, seemed to indicate that Y652 is involved in R-roscovitine 341 binding. This was disimiliar to the results for S624A hERG (Fig 4) , and made us question 342 whether additional residues in the pore region were involved in R-roscovitine inhibition, and 343 whether they would be more critical. 
370
With R-roscovitine binding to the hERG pore, it was likely that the large influx of K + ions 371 and the change in external solution would alter the WT hERG IC 50 . To determine the dose-372 response curves for R-roscovitine from WT tail currents, a pulsing protocol was applied, 373 comprised of a 1 second depolarization to +40 mV and a 1 second repolarization to -120 mV;
374 peak tail currents were measured in various R-roscovitine concentrations ( Figs 6A, B) . Fitting 511 intermolecular interactions. This was evident with the T623A hERG mutant, which exhibited an 512 overall weak tail current inhibition by R-roscovitine (Fig 7A) . Upon analysis the shift in E rev in 513 the presence of R-roscovitine, it was apparent that the drug was not altering permeation (Fig 7B) .
514 Furthermore, the larger IC 50 value for T623A hERG versus WT hERG suggested that the drug 515 efficacy was reduced by the mutation (Fig 7D) . Collectively, our data suggest the drug was no 516 longer able to bind in its original pore location. This level of inhibition loss could represent R-517 roscovitine's requirement of hydrogen-bonding to the hydroxyl group of T623 for maintaining 518 normal potency.
519 Surprisingly, step and tail current inhibition were not impacted by mutation to the S624 520 residue (Figs 4B, 4D ). In fact, inhibition levels increased in the S624A hERG mutant when 521 compared to WT inhibition at the same voltages ( Figs 4C, 4E) , and no general increase in IC 50 522 was apparent for S624A (Fig 4F 
